Adverum Biotechnologies, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2024 12 months to Dec 31, 2024	FY2023 12 months to Dec 31, 2023	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020
Cash flows from operating activities:
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization
Stock-based compensation expense
Net accretion of discount on marketable securities
Accreted interest on BPI
Impairment of goodwill and intangible assets
Non-cash lease expense
Non-cash sublease loss/(income)
Loss on disposal of property and equipment
Impairment of long-lived assets
Foreign currency remeasurement loss
Other

Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Operating lease right-of-use assets
Deposit and other long-term assets
Accounts payable
Accrued expenses and other liabilities
Deferred revenue
Deferred rent
Other non-current liabilities
Deferred tax liability
Lease liability

Net cash used in operating activities
Cash flows from investing activities:
Purchases of marketable securities
Maturities of marketable securities
Sales of marketable securities
Purchases of property and equipment
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Proceeds from offering of common stock, net of issuance costs
Proceeds from issuance of common stock and pre-funded warrants in private placement, net of issuance costs
Payment of deferred offering costs
Proceeds from issuance of common stock pursuant to option exercises
Taxes paid related to net share settlement of restricted stock units
Proceeds from employee stock purchase plan
Repayment of BPI loan
Proceeds from a financing arrangement
Net cash provided by financing activities

Net (decrease) increase in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash at beginning of period
Cash, cash equivalents and restricted cash at end of period
Supplemental schedule of noncash information
Right-of-use assets obtained in exchange for lease liability
Decrease in right-of-use asset and lease liability due to termination
Remeasurement of right-of-use asset on lease modification
Non-cash settlement of operating lease liability
Remeasurement of operating lease right-of-use assets and liabilities
Fixed assets in accounts payable and current liabilities
Cash and cash equivalents
Restricted cash

Comments